C1q shows synapse-class-specific roles, with inhibitory versus excitatory synapses exhibiting different susceptibility to C1q-associated elimination

Target: C1QA,C1QB,C1QC,GAD1,GAD2,SLC6A1,SLC17A7,ITGAM,ITGB2 Composite Score: 0.530 Price: $0.53 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.530
Top 69% of 1374 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.63 Top 54%
C+ Evidence Strength 15% 0.52 Top 62%
B Novelty 12% 0.64 Top 71%
B Feasibility 12% 0.60 Top 44%
C Impact 12% 0.43 Top 92%
F Druggability 10% 0.24 Top 95%
C Safety Profile 8% 0.47 Top 72%
B Competition 6% 0.66 Top 53%
C+ Data Availability 5% 0.58 Top 58%
C+ Reproducibility 5% 0.50 Top 67%
Evidence
2 supporting | 2 opposing
Citation quality: 0%
Debates
1 session B
Avg quality: 0.68
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Does C1q function differ based on subcellular localization or binding partner identity?

The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q. Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (5)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions
Score: 0.750 | Target: C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3
Microglial TREM2 state determines whether C1q-tagged substrates are cleared adaptively or converted into chronic complement-associated synaptotoxic inflammation
Score: 0.670 | Target: TREM2,TYROBP,C1QA,C1QB,C1QC,C3
C1q has spatially distinct functions, with synapse-bound C1q primarily nucleating complement-dependent pruning and microglia-associated C1q potentially modulating effector state through receptor-specific signaling
Score: 0.630 | Target: C1QA,C1QB,C1QC,C4A,C4B,C3,ITGAM,ITGB2,LAIR1
C1q effector output is determined more by binding partner identity than by subcellular location
Score: 0.610 | Target: C1QA,C1QB,C1QC,NPTX1,NPTX2,APP,C3
APOE isoform modifies the C1q binding landscape, biasing C1q toward inflammatory plaque-associated or synaptotoxic complexes in APOE4 contexts
Score: 0.590 | Target: APOE,C1QA,C1QB,C1QC,TREM2,APP

→ View full analysis & all 6 hypotheses

Description

This hypothesis is biologically plausible and potentially important for circuit-level phenotypes, but current support is stronger for contextual selectivity than for distinct intrinsic C1q biochemical programs at inhibitory versus excitatory terminals. It is more valuable for endpoint design and disease-stage interpretation than as a near-term therapeutic thesis.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.63 (15%) Evidence 0.52 (15%) Novelty 0.64 (12%) Feasibility 0.60 (12%) Impact 0.43 (12%) Druggability 0.24 (10%) Safety 0.47 (8%) Competition 0.66 (6%) Data Avail. 0.58 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.530 composite
4 citations 4 with PMID Validation: 0% 2 supporting / 2 opposing
For (2)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
MECH 4CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
AD mouse models show cell-type and synapse-class s…SupportingMECH----PMID:37118504-
Complement-mediated synapse loss is established, l…SupportingMECH----PMID:27033548-
Observed selectivity may arise from network activi…OpposingMECH----PMID:37118504-
Evidence does not yet show fundamentally distinct …OpposingMECH----PMID:37118504-
Legacy Card View — expandable citation cards

Supporting Evidence 2

AD mouse models show cell-type and synapse-class selective engulfment, consistent with possible circuit-biased…
AD mouse models show cell-type and synapse-class selective engulfment, consistent with possible circuit-biased C1q vulnerability.
Complement-mediated synapse loss is established, leaving room for differential class susceptibility across cir…
Complement-mediated synapse loss is established, leaving room for differential class susceptibility across circuits.

Opposing Evidence 2

Observed selectivity may arise from network activity, anatomy, or glial preference rather than synapse-intrins…
Observed selectivity may arise from network activity, anatomy, or glial preference rather than synapse-intrinsic C1q coding.
Evidence does not yet show fundamentally distinct C1q biochemical programs at inhibitory versus excitatory syn…
Evidence does not yet show fundamentally distinct C1q biochemical programs at inhibitory versus excitatory synapses.
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

  • Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling

  • Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis

    🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

    Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht

    🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Triage

    The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.

    The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.

    Per Idea

    `6. Spare C1q recognition, block C1r/C1s activation`

    • Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus

    Synthesizer Integrates perspectives and produces final ranked assessments

    {"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC

    Price History

    No price history recorded yet

    7d Trend
    Stable
    7d Momentum
    ▲ 0.0%
    Volatility
    Low
    0.0000
    Events (7d)
    0

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (2)

    Complement and microglia mediate early synapse loss in Alzheimer mouse models.
    Science (2016) · PMID:27033548
    No extracted figures yet
    Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models.
    Nature aging (2022) · PMID:37118504
    No extracted figures yet

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    📓 Linked Notebooks (1)

    📓 Does C1q function differ based on subcellular localization or binding partner identity? — Analysis Notebook
    → Browse all notebooks

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    Related Hypotheses

    TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
    Score: 0.990 | neurodegeneration
    TREM2-Dependent Microglial Senescence Transition
    Score: 0.950 | neurodegeneration
    PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
    Score: 0.941 | neurodegeneration
    Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
    Score: 0.933 | neurodegeneration
    CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
    Score: 0.921 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (0 edges)

    No knowledge graph edges recorded

    3D Protein Structure

    🧬 C1QA — PDB 1PK6 Click to expand 3D viewer

    Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

    Source Analysis

    Does C1q function differ based on subcellular localization or binding partner identity?

    neurodegeneration | 2026-04-25 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)